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Musgrove P. Judging health systems: reflections on WHO’s 2. 
methods. Lancet 2003;361:1817-20.
The Authors Reply: We welcome vigorous de-
bate about all aspects of assessment of health sys-
tem performance, with the ultimate goal of im-
proving the health of populations. The World 
Health Report 20001 generated a rich discussion 
that advanced this field of study enormously, lead-
ing to a 927-page volume published by the WHO 
in 20032 and feeding into health care reform ini-
tiatives in China, Mexico, Iran, and elsewhere.
Musgrove criticizes our Perspective article for 
citing rankings from the 2000 report. It is impor-
tant to note that he was one of the report’s lead 
authors and that 3 years after its publication, he 
took the unusual step of critiquing his own re-
port.3 At that time, we published a thorough re-
buttal.4
The United States spends more on health care 
and yet has worse rates of death and a higher dis-
ease burden than countries that spend far less. 
Apologists for the U.S. system tend to ignore these 
facts and attempt to distract observers from the 
real challenges the country faces. If we do not 
build a strong evaluation component into reform, 
we will miss opportunities for learning through 
implementation, correcting the course if needed, 
promoting accountability, and mustering public 
support. Unfortunately, on these critical points, 
Musgrove is silent.
Christopher J.L. Murray, M.D., D.Phil.
University of Washington  
Seattle, WA
Julio Frenk, M.D., Ph.D., M.P.H.
Harvard School of Public Health  
Boston, MA
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Failure to Validate Association between 12p13 Variants  
and Ischemic Stroke
To the Editor: Recently published data from a 
meta-analysis of genomewide association studies 
showed that two common single-nucleotide poly-
morphisms (SNPs) near the NINJ2 and WNK1 
genes on chromosome 12p13 were associated with 
ischemic and, in particular, atherothrombotic 
strokes.1 To validate these results, we conducted 
a meta-analysis in a combined sample of 8637 
cases and 8733 controls of European ancestry, as 
well as one population-based genomewide cohort 
study of 278 ischemic strokes among 22,054 par-
ticipants.
Both SNPs from the original report (rs12425791 
and rs11833579) were tested for association with 
ischemic stroke, as well as incident stroke, recur-
rent stroke, and stroke subtypes (according to the 
Trial of Org 10172 in Acute Stroke Treatment 
[TOAST] criteria2). We also conducted similar 
analyses in cases and controls of African-Amer-
ican ancestry and in samples from Chinese and 
Pakistani subjects. Furthermore, we evaluated gene 
expression for NINJ2 and WNK1 in 132 cases with 
ischemic stroke and in 80 controls, as well as the 
association of the chromosome 12p13 variants 
with the risk of hemorrhagic stroke. Details re-
garding the study design and extended results are 
available in the Supplementary Appendix, available 
with the full text of this letter at NEJM.org.
We found no association between rs12425791 
and ischemic stroke (odds ratio, 0.97; 95% confi-
dence interval [CI], 0.91 to 1.04; P = 0.41) or be-
tween rs11833579 and ischemic stroke (odds ratio, 
1.02; 95% CI, 0.95 to 1.10; P = 0.55) in persons of 
European ancestry (Fig. 1). We found no asso-
ciation between either of the SNPs and athero-
thrombotic stroke in 2235 cases (P>0.10) (Fig. 2) 
and no association between either of the SNPs 
and incident ischemic stroke, recurrent is chemic 
stroke, and ischemic stroke subtypes (P>0.10 for 
all comparisons). The power to detect an associa-
tion at an effect size below the lower limit of the 
95% confidence interval surrounding the original 
estimate exceeded 99% for ischemic as well as 
atherothrombotic stroke. We observed no differ-
ences in gene expression between cases and 
controls and no association between either of 
the SNPs and a risk of hemorrhagic stroke. Het-
erogeneity in meta-analyses of our studies was 
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Figure 1. Associations between Single-Nucleotide Polymorphisms (SNPs) and Ischemic Strokes in Persons  
of European Ancestry, According to Study.
The forest plots show the odds ratios for the association between ischemic strokes and the minor allele (A) of both SNPs. 
No risk effect of these alleles was detected for either SNP. Data from 8915 persons with ischemic strokes are shown. The 
comparison group is 30,510 stroke-free controls. Individual studies (blue boxes) are plotted against the individual effect 
sizes (odds ratios). The red diamonds indicate overall odds ratios. The size of the blue boxes indicates study-specific 
weights for the meta-analysis. Horizontal lines indicate 95% confidence intervals. The dashed vertical line shows the lack 
of any effect on the risk of stroke (odds ratio, 1.0). ESS denotes Edinburgh Stroke Study, GCNKSS Greater Cincinnati/
Northern Kentucky Stroke Study, ISGS Ischemic Stroke Genetics Study, MCISS Middlesex County Ischemic Stroke Study, 
MGH Massachusetts General Hospital, MIGen Myocardial Infarction Genetics Consortium, SWISS Siblings with Ische-
mic Stroke Study, UMD-SPYAS University of Maryland Stroke Prevention in the Young Study, VISP Vitamin Intervention 
for Stroke Prevention Trial, WGHS Women’s Genome Health Study, WTCCC2:GER Wellcome Trust Case–Control Con-
sortium 2, German data, and WTCCC2:UK Wellcome Trust Case–Control Consortium 2, United Kingdom data.
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not significant (P>0.20 for heterogeneity, pro-
portion of total variation in study estimates be-
cause of heterogeneity in the meta-analysis [I2] 
<20%),3 although we did identify significant 
heterogeneity in the original report’s meta-analy-
ses for rs11833579 (P = 0.07 for heterogeneity, 
I2 = 56.1%) and rs12425791 (P = 0.15 for heteroge-
neity, I2 = 42.1%).1
Our well-powered meta-analyses did not vali-
date previously reported associations between two 
SNPs (rs12425791 and rs11833579) and stroke.1 
This lack of validation is most likely because of 
a false positive result in the previous meta-analy-
sis. Differences between our predominantly case–
control sample and the cohort sample of the 
original study may also have been factors. Given 
the power of our meta-analysis, a false negative 
finding is unlikely. Our results strongly suggest 
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Figure 2. Associations between Single-Nucleotide Polymorphisms (SNPs) and Atherothrombotic Strokes in Persons  
of European Ancestry, According to Study. 
The forest plots show the odds ratios for the association between atherothrombotic strokes and the minor allele (A) 
of both SNPs. No risk effect of these alleles was detected for either SNP. Data from 2235 persons with atherothrom-
botic strokes are shown. The comparison group is 30,510 stroke-free controls. Individual studies (blue boxes) are 
plotted against the individual effect sizes (odds ratios). The red diamonds indicate overall odds ratios. The size of 
the blue boxes indicates study-specific weights for the meta-analysis. Horizontal lines indicate 95% confidence in-
tervals. The dashed vertical line shows the lack of any effect on the risk of stroke (odds ratio, 1.0).
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Autologous Pancreatic Islet Transplantation for Severe Trauma
To the Editor: Autologous pancreatic islet 
transplantation has been successfully carried out 
after total pancreatectomy for chronic pancreati-
tis, and allogeneic islet-cell transplantation has 
had limited success.1,2 We report a case of suc-
cessful islet transplantation from the pancreas 
after total pancreatectomy because of trauma.
A 21-year-old airman serving in a remote part 
of Afghanistan was hit by three high-velocity 
bullets on November 21, 2009, and was rapidly 
transferred to Walter Reed Army Medical Center. 
As part of needed rescue surgery, a portion of the 
stomach, the gallbladder, the entire duodenum, 
and the head of the pancreas were removed. In 
addition, the patient required left hemicolectomy 
and resection of a portion of the small bowel.
During the attempt to reconstruct the intraab-
dominal structures, the remnant pancreas (weigh-
ing 63.5 g, approximately half the entire pancreas) 
was found to be damaged from the effects of the 
gunshot wounds and was leaking pancreatic en-
zymes and dissolving critical abdominal struc-
tures and blood vessels. We decided to remove 
the entire remaining pancreas to prevent further 
leakage, breakdown, and bleeding, which could 
be fatal. The pancreas was flushed with Univer-
sity of Wisconsin solution, packed in ice, and 
transported to the University of Miami. The is-
lets (221,250 islet equivalents of 40% purity and 
90% viability) were shipped back to Walter Reed, 
where by laparotomy they were injected back into 
the patient’s main portal vein so as to seed in the 
liver. Portal pressures remained normal through-
out the infusion. 
Levels of C-peptide in basal and stimulated 
(after an oral glucose-tolerance test) conditions 
were 0.5 ng per milliliter with a glucose level of 
80 mg per deciliter (fasting) and 3.9 ng per mil-
liliter with a glucose level of 184 mg per deciliter 
(stimulated). As of postoperative day 114, the pa-
tient had normal islet function. Liver enzymes 
peaked on day 3 (800 IU for aspartate aminotrans-
ferase and 900 IU for alanine aminotransferase) 
and normalized on day 8. The patient was able to 
discontinue insulin on day 24. Initially, he required 
a small amount of insulin (1 to 2 units per hour) 
for total parenteral nutrition and 11 serial surgi-
cal procedures to close his abdomen. As of day 
20, the patient was eating a normal diet.
In this patient, we were able to isolate and 
transplant insulin-producing cells after a severe 
trauma requiring complete removal of the pan-
creas. This procedure may prevent diabetes and 
secondary complications if even a small portion 
of pancreas can be salvaged. We also showed the 
feasibility of sending a pancreas to a remote lo-
cation for islet isolation and purification and then 
transporting the islets back for successful infu-
sion within 24 hours.3
Rahul M. Jindal, M.D., Ph.D.
Walter Reed Army Medical Center 
Washington, DC 
jindalr@msn.com
Camillo Ricordi, M.D.
University of Miami Diabetes Research Institute 
Miami, FL
Craig D. Shriver, M.D.
Walter Reed Army Medical Center 
Washington, DC
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